Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-cash Items (2017 - 2024)

Historic Non-cash Items for Coherus Oncology (CHRS) over the last 10 years, with Q4 2024 value amounting to $17.0 million.

  • Coherus Oncology's Non-cash Items fell 5451.63% to $17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $17.0 million, marking a year-over-year decrease of 5451.63%. This contributed to the annual value of $17.0 million for FY2024, which is 5451.63% down from last year.
  • As of Q4 2024, Coherus Oncology's Non-cash Items stood at $17.0 million, which was down 5451.63% from $37.4 million recorded in Q4 2023.
  • Over the past 5 years, Coherus Oncology's Non-cash Items peaked at $72.4 billion during Q4 2020, and registered a low of $17.0 million during Q4 2024.
  • Over the past 5 years, Coherus Oncology's median Non-cash Items value was $51.5 million (recorded in 2022), while the average stood at $14.5 billion.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 7711538.96% in 2020, then plummeted by 9991.52% in 2021.
  • Quarter analysis of 5 years shows Coherus Oncology's Non-cash Items stood at $72.4 billion in 2020, then tumbled by 99.92% to $61.4 million in 2021, then decreased by 16.12% to $51.5 million in 2022, then decreased by 27.38% to $37.4 million in 2023, then tumbled by 54.52% to $17.0 million in 2024.
  • Its last three reported values are $17.0 million in Q4 2024, $37.4 million for Q4 2023, and $51.5 million during Q4 2022.